➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
AstraZeneca
Express Scripts
Merck
McKinsey

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

SUPPRELIN LA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Supprelin La patents expire, and when can generic versions of Supprelin La launch?

Supprelin La is a drug marketed by Endo Pharm and is included in one NDA. There is one patent protecting this drug.

This drug has three patent family members in three countries.

The generic ingredient in SUPPRELIN LA is histrelin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the histrelin acetate profile page.

US ANDA Litigation and Generic Entry Outlook for Supprelin La

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for SUPPRELIN LA
Drug Prices for SUPPRELIN LA

See drug prices for SUPPRELIN LA

Recent Clinical Trials for SUPPRELIN LA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Southwest Oncology GroupPhase 3
National Cancer Institute (NCI)Phase 3
University of Colorado, DenverPhase 2

See all SUPPRELIN LA clinical trials

US Patents and Regulatory Information for SUPPRELIN LA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharm SUPPRELIN LA histrelin acetate IMPLANT;SUBCUTANEOUS 022058-001 May 3, 2007 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SUPPRELIN LA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharm SUPPRELIN LA histrelin acetate IMPLANT;SUBCUTANEOUS 022058-001 May 3, 2007   Start Trial   Start Trial
Endo Pharm SUPPRELIN LA histrelin acetate IMPLANT;SUBCUTANEOUS 022058-001 May 3, 2007   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
AstraZeneca
Express Scripts
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.